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Abstract
Disruption of ribosomal proteins is associated with hematopoietic phenotypes in cell culture and
animal models. Mutations in ribosomal proteins are seen in patients with Diamond Blackfan
anemia (DBA), a rare congenital disease characterized by red cell aplasia and distinctive
craniofacial anomalies. A zebrafish screen uncovered decreased hematopoietic stem cells (HSCs)
in embryos with mutations in ribosomal protein rps29. Here, we determined that rps29-/- embryos
also have red blood cell defects and increased apoptosis in the head. As the p53 pathway has been
shown to play a role in other ribosomal protein mutants, we studied the genetic relationship of
rps29 and p53. Transcriptional profiling revealed that genes up-regulated in the rps29 mutant are
enriched for genes up-regulated by p53 after irradiation. p53 mutation near completely rescues the
rps29 morphological and hematopoietic phenotypes, demonstrating that p53 mediates the effects
of rps29 knockdown. We also identified neuronal gene orthopedia protein a (otpa) as one whose
expression correlates with rps29 expression, suggesting that levels of expression of some genes
are dependent on rps29 levels. Together, our studies demonstrate a role of p53 in mediating the
cellular defects associated with rps29 and establish a role for rps29 and p53 in HSCs and red blood
cell development.
Keywords
Diamond Blackfan anemia; hematopoietic stem cells; ribosomal proteins
Introduction
Diamond Blackfan anemia (DBA) is a rare, congenital anemia often diagnosed by one year
of age[1]. Patients with DBA have a block in erythropoiesis, and often have craniofacial
anomalies. It is also thought that patients may have an HSC defect, as they may develop
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tbone marrow failure and aplastic anemia. Treatment regimens include transfusions and
steroids, but currently the only cure is hematopoietic stem cell transplant.
Over 50% of patients have a mutation in a ribosomal protein gene[2]. Pathogenic mutations
in RPS19[3], RPS24[4], RPS17[5], RPL35A[6], RPL5, RPL11, RPS7[7], RPS10, and
RPS26[8] have been identified in patients. Patients are always heterozygous for the
mutations and maintain one copy of the unmutated ribosomal protein. In addition, some
family members have been identified to have a mutation in a DBA gene but have only mild
or no symptoms. The mechanism behind the incomplete penetrance seen in families is still
unknown and suggests that other genetic modifiers exist.
Why ribosomal protein mutations specifically affect hematopoiesis is still unclear. To
address the mechanism, several models of ribosomal protein mutation have been developed,
including mouse models and shRNA knockdown in human cells. The first mouse model
generated, an rps19 knockout, was homozygous lethal[9]. Heterozygous mice did not have a
phenotype, but the wildtype rps19 locus was found to be upregulated, compensating for the
mutant allele[10]. However, mice with a point mutation in rps19 do have a hematopoietic
defect that is rescued by p53 knockdown[11]. p53 inactivation also rescues craniofacial
abnormalities in mouse models of Treacher Collins Syndrome, where mutations affect
ribosome biogenesis[12]. In a mouse model of conditional rps6 knockdown, p53 is
activated[13]. Mechanistic studies in this system suggest that levels of some free ribosomal
proteins are increased as a result of impaired ribosome biogenesis. These free ribosomal
proteins, including rpL11 and rpL5, can enter the nucleus, bind mdm2, and sequester it from
p53. Thus, rpL11 mediates the p53 activation seen in the rps6 knockdown mice, and this
mechanism may hold true for other models of ribosomal protein knockdown.
Several groups have previously used zebrafish for modeling ribosomal protein knockdown,
as zebrafish hematopoietic regulation is conserved with mammals and the model system is
particularly amenable for high throughput in vivo genetics. Ribosomal protein mutants have
been generated[14], or these genes can be knocked down in the embryo with morpholino
technology. Zebrafish embryos homozygous for ribosomal protein mutations can survive for
several days, likely the result of maternal RNA and protein contribution. Morpholinos
against rps19 and rpL11[15-17], as well as an rpL11 mutant[18], recapitulate many aspects
of the DBA phenotype, including hematopoietic specific defects and p53 activation.
Our lab previously identified a zebrafish ribosomal protein mutant with defects in
hematopoietic stem cell (HSC) development. Rps29, a protein in the 40s small subunit of the
ribosome important for rRNA processing and ribosome biogenesis[19], was found to be
required for definitive hematopoiesis in the zebrafish embryo[20]. The rps29 mutant has
decreased HSC markers runx and myb at 36 hours post fertilization (hpf) in the aorta gonad
mesonephros (AGM) region. At this stage of development, definitive HSCs emerge from the
hemogenic endothelium lining the aorta[21]. Thus, endothelial cell fate specification,
vasculogenesis, and the establishment of artery identity are all required for HSC formation.
In the rps29 mutant, vasculogenesis occurs normally, but artery identity is not established as
shown by lack of flk1-expressing intersomitic vessels and ephrinB2 expression. Therefore,
the HSC defect is likely the result of a defect in aorta specification.
Here, we describe new aspects of the rps29 mutant phenotype that include defects in red
blood cell development and an increase in apoptotic cells. To understand what pathways
mediate this phenotype, we performed microarray analyses on both rps29 mutants and p53
mutants. Analysis of microarray data from the rps29 mutant embryos uncovered differential
expression of genes associated with apoptotic pathways and a gene whose levels correlate
with rps29 levels. Using gene set enrichment analysis (GSEA), we found that genes up-
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tregulated in the rps29 mutant were enriched for genes activated by p53 upon irradiation.
When p53 is mutated in homozygous rps29 mutant embryos, the apoptotic and
hematopoietic phenotypes are rescued. Our microarray data also identified a neuronal gene,
otpa, whose expression correlated with rps29 level. However, p53 mutation does not fully
rescue expression of this gene, suggesting that other p53-independent mechanisms are
affected by rps29 knockdown. Our data support a model where p53 activation results from
ribosomal protein deficiency and mediates the hematopoietic phenotype.
Materials and Methods
Zebrafish maintenance and lines
Fish were maintained under approved laboratory conditions. The two fish lines used are:
hi2903, an insertional mutant in the first intron of rps29[14], and p53M214K/M214K, a p53
point mutant in the DNA-binding domain[22].
In situ hybridization, stains, and immunohistochemistry
Whole-mount in situ hybridization was performed as described[23]. Antisense probes were
synthesized from digested plasmid or PCR product template. O-dianisidine was performed
as previously described[24]. Embryos treated with 1-phenyl 2-thiourea (PTU) to prevent
pigmentation were stained with Sudan Black as previously described[25]. TUNEL staining
was performed according to manufacturer's instructions using Millipore's ApopTag® Plus
Peroxidase In Situ Apoptosis Kit. Globin antibody staining was performed as described[25]
using a zebrafish antibody from Anaspec (Anti-Hbbe, Catalog Number 55608).
Quantitative PCR and microarrays
RNA was isolated from zebrafish embryos using Trizol and according to the manufacturer's
directions. cDNA was made using the Invitrogen Superscript III First-Strand Synthesis
system. Quantitative PCR was performed using Bio-Rad Ssofast EvaGreen Supermix and
published primer sequences are available upon request. For the rps29 microarrays, 24 hpf
mutant embryos were separated from wildtype and heterozygous siblings by morphology,
and the wildtypes and heterozygotes were pooled together. 3 pairs of samples (6 total) were
sent for analysis on a Nimblegen microarray. For the p53 microarray, wildtype (Tu) and
p53M214K/M214K embryos received 16 Gy of gamma irradiation at 27 hpf. RNA isolation
was performed on pooled embryos one hour post irradiation. A total of 12 samples were
analyzed, 3 of each class (wildtype unirradiated, wildtype irradiated, p53M214K/M214K
unirradiated, and p53M214K/M214K irradiated), and were hybridized to Affymetrix zebrafish
arrays. For otpa and βe3 globin expression, tail DNA from 24 or 40 hpf embryos was used
for genotyping. Five embryos of the same genotype were pooled for cDNA synthesis and
qPCR.
Bioinformatics analysis
Differential gene sets were generated utilizing the Goldenspike workflow[26], identifying
genes significantly different amongst groups with q values<0.05. To overcome annotation
differences between the array platforms, we mapped the Nimblegen probe that corresponded
to the appropriate Affymetrix probe. Rps29 microarray data was analyzed using Ingenuity
Pathway Analysis (IPA) to identify pathways significantly affected in the rps29 mutant. For
the GSEA analysis, we identified a gene signature of the rps29 mutants consisting of 524
up-regulated and 442 down-regulated genes. These were then used as a query set to identify
enrichment within the p53 dataset using GSEA v2.
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RPS29 is required for definitive HSCs and primitive RBCs
Zebrafish embryos undergo both primitive and definitive waves of hematopoiesis. We
wanted to determine the effects of an rps29 insertional mutation[14] on these waves in the
zebrafish. Rps29-/- embryos survive for five days[27], probably due to maternal rps29
protein deposited in the embryo. We previously showed that rps29-/- embryos have
decreased definitive HSC formation, likely the result of a defect in aorta specification[20].
Because ribosomal proteins are mutated in patients with erythroid specific deficiencies, we
hypothesized that the zebrafish rps29 mutation might also cause a defect in primitive red
blood cell development independent of the definitive HSC defect. In the zebrafish embryo,
primitive erythropoiesis begins in the posterior lateral plate mesoderm, and blood cells can
be seen in circulation soon after 24 hpf[28]. Using whole mount in situ hybridization [29],
we analyzed rps29 mutants for gata1, a marker of erythroid precursors, and βe3 globin,
which also marks more mature erythrocytes. Gata1 expression in primitive erythroid cells
and precursors appears normal at the 18 somite stage (ss) in the rps29 mutant, and βe3
globin levels in the erythroid lineage at 40-48 hpf are unaffected (Figure 1A and 1B). RNA
levels of αe1 and αe3 are comparable between heterozygous and mutant embryos, as
determined by qPCR (Supplemental Figure 1). βe3 globin protein levels were also
unchanged in the rps29 mutant (Figure 1A). In contrast, at the same stage, o-dianisidine
(benzidine) staining is decreased (15 out of 21 embryos affected, Fisher's exact
p=4.15×10-13), demonstrating a decrease in hemoglobin levels (Figure 1A). These data
indicate a late stage defect in red cell differentiation or hemoglobinization and are
suggestive of a hypochromic anemia that is typically due to a lack of iron, heme, or globin
expression[30]. In contrast, primitive granulocytes remain unaffected, as determined by mpo
RNA expression at 24 hpf and Sudan Black staining for mature granulocytes at 34 hpf
(Figure 1C), suggesting an erythroid specific defect in primitive hematopoiesis. A summary
of the mutant phenotypes, both primitive and definitive, is shown in Supplemental Figure 2.
Microarray identifies hematopoietic, skeletal, and neural pathways affected in the rps29
mutant
To identify pathways and gene networks affected by the rps29 mutation, we performed a
Nimblegen microarray comparing 24 hpf rps29 homozygous mutants vs. their heterozygous
and wildtype siblings (Figure 2A). Because wildtype and heterozygous embryos cannot be
separated by morphology, they were pooled for the microarray analysis. Rps29 was the most
down-regulated gene, and rps29 levels are decreased in both heterozygous and homozygous
embryos as early as 8ss (Figure 2B). Approximately 1000 genes were differentially
regulated (Supplemental Table 1). To highlight statistically significant pathways from this
list, we used Ingenuity Pathway Analysis (IPA). Tissue-specific pathways, including blood,
skeleton, and neuron development, were among the pathways altered by rps29 mutation
(Figure 2C). We assayed representative genes from these pathways by ISH, allowing
analysis of individual wildtype, heterozygous, and mutant embryos. Genes involved in
hematopoiesis, including bcl11a and Notch, were decreased in homozygous mutants but not
in heterozygous embryos (data not shown). However, orthopedia protein a (otpa), a
homeobox containing gene expressed in the brain by 24 hpf[31], was affected in both
heterozygous and homozygous mutants. Otpa levels were substantially decreased in the
homozygous mutant embryo, but ISH analysis revealed that over one-third of heterozygous
embryos had an intermediate phenotype (9 embryos out of 24, Fisher's exact p=0.0013)
(Figure 2D). This was confirmed by qPCR (Figure 2E). Amongst the genes we examined by
ISH, otpa is the only one that showed a distinct heterozygous vs. homozygous phenotype.
The existence of a gene whose levels directly correlate to the expression of a ribosomal
protein suggests a dose-dependent mechanism.
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As genes involved in cell cycle, cell death, and metabolism were also identified by gene
expression studies with microarrays, we determined if proliferation was affected or
apoptosis was aberrantly induced at 24 hpf. By flow activated cell sorting (FACS) analysis
on whole embryos treated with propidium iodide, we generated cell cycle profiles. We
determined that the profile of homozygous mutant embryos was not different from their
wildtype and heterozygous siblings, suggesting that cell cycle progression is not affected
(Figure 3A). In contrast, there is an increase in TUNEL-positive cells in the rps29 mutant
compared to wildtype and heterozygous siblings, particularly in the head (7/8 mutant
embryos, Fisher's exact p=0.001), demonstrating increased apoptosis (Figure 3B). We
looked at p53 and its target p21 by quantitative PCR, and this assay confirmed p53 and p21
RNA levels were up-regulated over 3-fold in the 24 hpf rps29 mutant embryos (Figure 3C).
These data indicate that a p53 apoptotic pathway is being activated in the mutant, mediated
by p21 activation.
p53-dependent irradiation signature activated in the rps29 mutant
Based on these data and data from the literature[32], we hypothesized that rps29 loss acts
similarly to p53 activation. To assess this idea at the gene expression level, we compared the
rps29 deficiency transcriptional profile to that of a p53 activation signature. To generate a
p53 activation signature by microarray, we analyzed the transcriptome of both wildtype and
p53M214K/M214K mutant embryos. (The p53M214K mutation is in the DNA binding domain.)
We used gamma-radiation to activate p53, as radiation is an insult that is known to activate
the p53 pathway[33]. We have previously shown that the p53 mutant no longer up-regulates
p21 in response to irradiation[22]. We performed an Affymetrix microarray on the following
four groups of 27 hpf embryos (in triplicate): wildtype unirradiated, wildtype irradiated,
p53M214K/M214K unirradiated, and p53M214K/M214K irradiated (Supplemental Table 2).
Comparing wildtype embryos to p53 mutants produces a list of genes affected by basal
levels of p53, but does not identify genes up-regulated upon p53 activation. We compared
wildtype unirradiated and irradiated lists to generate a p53 activation signature, and we
excluded genes that failed to be up-regulated in p53M214K/M214K mutant embryos to ensure
that the irradiation signature was specific to p53.
We then used gene set enrichment analysis (GSEA) to compare the genes up-regulated in
the rps29 mutant to the p53 dataset. The genes up-regulated in the rps29 mutant were
enriched for genes up-regulated in response to irradiation (Figure 4A). Of the 31 genes up-
regulated in response to irradiation, 22 are also up-regulated in the rps29 mutant (Figure
4B). None of these 22 genes are up-regulated in the p53 mutant post irradiation. This result
confirms that the gene expression signature of the rps29 mutant is similar to p53-dependent
radiation responsive genes. The enriched gene list includes genes involved in DNA damage
response and apoptosis, such as GADD45AL and BAX (Figure 4C). Our data demonstrate
that the p53 pathway is being activated in the rps29 mutant, and suggest that mutations in
p53 may rescue the rps29 mutant phenotype.
p53 mutation rescues the rps29 mutant phenotype
To test our hypothesis that the rps29 mutant phenotype was also p53 dependent in vivo, we
generated rps29-/-;p53M214K/M214K embryos. The following phenotypes were restored to
wildtype levels in double mutants compared to the rps29 homozygous mutant: head
morphology (18/18 mutant embryos rescued), TUNEL staining (2/2), o-dianisidine staining
(7/7), HSC markers (5/5), and flk1 expression in the intersomitic vessels (11/11) (Figure 5A-
D, Figure 3B). The ability of the p53 mutation to rescue these phenotypes demonstrates that
p53 activation is involved in the rps29 mutant phenotype. However, p53 mutation could not
rescue the embryonic lethality of rps29 mutants. The inability to rescue embryonic lethality
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tis likely because once maternal rps29 is completely lost, embryos can no longer make new
ribosomes, as has been demonstrated in mammalian cell culture[19]. Even if p53 is also
removed, the embryos still cannot make new proteins and therefore will die without rps29.
We also looked at otpa levels in p53M214K/M214K;rps29-/- embryos; although otpa was not
restored to WT levels, it had higher expression than rps29-/- alone (4/7 mutant embryos,
Figure 5F). In the case of the otpa phenotype, other mechanisms may be involved in addition
to p53 activation. Our studies of the rps29 mutant were able to identify p53 as a modifier of
the mutant phenotype, and this system can be used to identify novel modifiers of ribosomal
protein mutation.
Discussion
Ribosomal protein mutations in genes such as rps19 and rpL11 cause blood specific defects,
and this is seen in patients with DBA. We described erythroid and HSC defects in the
zebrafish embryo resulting from homozygous mutation of rps29, a protein in the 40s small
subunit of the ribosome. We identified a gene expression signature of p53 activation in the
rps29 mutant and tested the role of p53 activation genetically by generating rps29-/-;p53-/-
embryos. Loss of p53 rescues all of the hematopoietic and morphological phenotypes in the
rps29 mutant that we tested. Skeletal and neuronal tissues are also affected, including a
gene, otpa, whose expression is dependent on rps29 expression level.
Our work builds upon the previously characterized HSC and artery defects of the rps29
mutant[20]. We went on to characterize red blood cells in the mutant, as ribosomal protein
mutations cause erythroid specific defects in patients with DBA. (N.B. Mutations in rps29
have not been found in DBA patients.) Red blood cells in the homozygous rps29 mutant are
indeed affected as hemoglobin levels are decreased. Since embryonic globin RNA is normal,
this defect may be at a terminal stage of differentiation or specific to hemoglobinization.
This phenotype is in contrast with the erythroid progenitor block seen in DBA patients, but
mirrors what is seen in the zebrafish rps19 morphant and rpL11 mutant. Although the
specific stage of the erythropoietic defect differs in zebrafish ribosomal protein mutants and
patients, the trends of the zebrafish mutants phenocopy DBA in both skeletal and
hematopoietic tissues. Erythroid cells are affected, but myeloid tissues remain largely
unaffected in both cases. Mechanistically, the role of p53 activation in the rps29 mutant is
consistent with other ribosomal protein mutants and DBA models.
Our data demonstrate that p53 is a mediator of the rps29 mutant phenotype. Previous studies
have suggested a critical role for p53 in ribosomal protein mutant phenotypes, and our
findings extend this observation to an additional ribosomal protein, rps29. GSEA shows
strong enrichment for a p53 activation gene signature, as 22 out of 31 genes in a p53-
dependent irradiation signature are also up in the rps29 mutant. Studies from others suggest
that the mechanism of p53 activation is nucleolar/ribosomal stress[13]. In this model, a
mutated ribosomal protein prevents ribosomal subunit formation, leading to an increase in
free ribosomal proteins. Some of these, including rpL11 and rpL5, can bind mdm2 and
sequester it from p53, leading to p53 activation. Our data suggest that the mechanism of p53
activation in the mutant mirrors that of irradiation, the source of p53 activation in our
analysis. Interestingly, there is evidence that some DNA damage agents can initiate
ribosomal stress[34], and a common pathway could explain the similar gene signatures.
However, the downstream targets of p53 in the rps29 mutant are not yet fully elucidated.
It is interesting that p53 knockdown also rescues the hemoglobin defect, as this suggests that
p53 activation is causing the hemoglobin defect. Other zebrafish studies have tested the role
of p53 activation with conflicting results; a p53 morpholino rescues the hemoglobin defect
in the rpL11 mutant, but does not rescue the defect induced by rps19 morpholino
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tknockdown[16, 18]. Interestingly, morpholino knockdown of telomerase reverse
transcriptase (TERT) in zebrafish embryos also causes apoptosis and hematopoietic specific
defects[29]. Like the rps29 mutant, many of the zTERT morphant phenotypes are p53-
dependent; in contrast, the zTERT hemoglobin defect cannot be rescued by p53 knockdown.
The reason for these discrepancies is unclear, but could be the result of differences between
mutants and morpholino knockdown. Homozygous embryos can get maternally deposited
RNA from a heterozygous parent, whereas an ATG morpholino would inhibit translation of
maternal RNAs and cause a more severe knockdown, making rescue more difficult. We still
do not know how p53 activation inhibits heme biosynthesis. One hypothesis is based on
evidence that p53 in the mitochondria is involved in heme biosysthesis and iron-sulfur (Fe-
S) cluster formation. Heme biosynthesis requires synthesis of ALAS2, which our lab has
previously shown to be inhibited when Fe-S cluster biogenesis is impacted[30]. Assembly of
Fe-S clusters requires intact mitochondria[35], but p53 activation causes mitochondrial
membrane permeabilization[36]. In this model, p53 activation would affect Fe-S cluster
biogenesis and subsequent heme biosynthesis, and the effect would be rescued by p53
knockdown.
An advantage of using a zebrafish mutant for these studies is the ability to compare both
heterozygous and homozygous mutants, and subsequently identify gene expression patterns
that correlate with rps29 level. Although we could not separate wildtype and heterozygous
embryos for the microarray, we could still identify dosage specific defects by whole mount
ISH. Orthopedia protein a (otpa) is a homeobox containing gene expressed in the brain and
important for neuron development[31], and the levels of otpa depend on rps29 levels. The
existence of dose-dependent genes with respect to a ribosomal protein suggests a dosage
sensitivity model. In wildtype embryos, the ribosome can function normally, translation
occurs normally, and genes such as myb, flk1, and otpa are expressed as expected. In the
homozygous rps29 mutant, there is a downstream effect on myb, flk1, and otpa expression.
When only one copy of rps29 is mutated, only otpa is down-regulated and many other genes
are unaffected. An alternate hypothesis is that otpa expression is not differentially regulated,
but stability of otpa mRNA is affected by rps29 mutation. Regulation of RNA expression or
stability could still be dose-dependent on rps29 mRNA levels. Interestingly, there are cases
where relatives of DBA patients have the same mutation but milder symptoms of the
disease, and this may be the result of different expression levels of the functional ribosomal
protein. Our data are in agreement with the hypothesis that differences of a ribosomal
protein level could cause a change in disease presentation.
p53 mutation partially rescues otpa in the homozygous mutant to heterozygous levels,
suggesting that p53 activation may play a role in both the heterozygous and homozygous
rps29 phenotype. The fact that p53 mutation only partially rescues otpa mRNA levels
further suggests that otpa is affected by rps29 knockdown by both p53-dependent and p53-
independent mechanisms. It is possible that a protein not efficiently translated in the rps29
heterozygote (or homozygote) directly regulates otp transcription, leading to a dose-
dependent decrease in otpa mRNA expression in the rps29 mutant. Another possibility is
that otpa directly interacts with the ribosome. There may also be a p53-independent stress
signal in the rps29 heterozygote and homozygote, causing some neuronal tissues to die
without p53 activation. Further testing is required to determine the exact p53-independent
mechanism causing a decrease of otpa mRNA in the rps29 mutant.
There are still lingering questions about the exact mechanism downstream of ribosomal
protein mutation, and modifier screens in the zebrafish could address these questions. The
zebrafish embryo is amenable to in vivo chemical and genetic screens. For example, a
genetic screen for rescue of the rps29 mutant would identify novel pathways, p53 dependent
or independent, mediating the mutant phenotype. These pathways can provide insight into
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texactly how erythropoiesis and HSC formation are affected by ribosomal protein mutation
and p53 activation. An in vivo chemical screen for compounds that rescue the hematopoietic
defect would identify therapeutics that may be more likely to translate to patients than hits
from an in vitro screen. The unique advantages of a zebrafish DBA model and ribosomal
deficiencies hold promise for the field of ribosomal protein biology.
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tFigure 1. Zebrafish rps29 mutant has a late-stage erythropoietic defect
(A) Whole embryo ISH for blood markers - gata1 at 18 somites; βe3 globin at 40-48 hpf.
Fluorescence antibody staining for βe3 globin at 48 hpf. O-dianisidine (benzidine) stain at
40 hpf.
(B) RT-PCR for βe3 globin. Data shown are fold changes of expression in rps29+/+ and
rps29+/- embryos compared to rps29-/- siblings at 40 hpf.
(C) Whole embryo ISH for mpo at 24 hpf; Sudan Black stain at 34 hpf.
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tFigure 2. Rps29 mutant microarray reveals dose-dependent genes
(A) Microarray schematic. Rps29+/- fish were incrossed, and mutant embryos were sorted at
24 hpf. RNA was isolated from sibling embryos and mutant embryos for microarray.
(B) Rps29 expression at the 8 somite stage by whole mount ISH.
(C) Pathways significantly affected in the rps29 mutant, identified by Ingenuity Pathway
Analysis.
(D) Dose-dependent expression of otpa. Orthopedia protein a (otpa) levels were assayed by
ISH at 24 hpf. Expression can be seen in the telencephalon and hindbrain.
(E) RT-PCR for otpa. Data shown are fold changes of expression in rps29+/- and rps29-/-
embryos compared to wildtype siblings at 24 hpf.
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tFigure 3. Apoptosis is induced in rps29-/- embryos
(A) Cell cycle analysis. Propidium iodide was used to generate a cell cycle profile of rps29
homozygous mutants and their heterozygous and wildtype siblings at 24 hpf.
(B) TUNEL staining. TUNEL staining was performed on 24 hpf embryos from a rps29+/-
incross, as well as embryos from a p53; rps29+/- incross.
(C) RT-PCR for p53 and p21. Data shown are fold changes of expression in rps29-/- mutant
embryos compared to their heterozygous and wildtype siblings at 24 hpf.
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tFigure 4. GSEA identifies a p53-dependent irradiation signature in rps29 mutants
(A) GSEA enrichment plot comparing genes up-regulated in the rps29-/- embryo to genes
up-regulated in wildtype embryos in response to irradiation.
(B) Comparison of gene lists. Of the 31 genes up-regulated in the wildtype embryo post-
irradiation, 22 are also up-regulated in the rps29 mutant. There are no genes that overlap
between all 3 lists: rps29 mutant, wildtype irradiated, and p53 irradiated.
(C) Genes up-regulated in both rps29-/- embryos and wildtype irradiated embryos.
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tFigure 5. p53 mutation rescues the rps29 mutant
(A) Morphology of embryos at 24 hpf.
(B) Hemoglobin at 40-48 hpf measured by staining with o-dianisidine (benzidine).
(C) HSCs at 36 hpf measured by ISH for myb.
(D) Vasculature at 24 hpf assayed by ISH for flk1.
(E) Otpa expression at 24 hpf assayed by ISH.
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